Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients

Clinical Biochemistry

Volumn 46, Issue 15, 2013, Pages 1462-1468

  Leung, F ^a,b   Dimitromanolakis, A ^b   Kobayashi, H ^c   Diamandis, E P ^a,b,d   Kulasingam, V ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c NARA MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Biomarker; CA125; Diagnostic; Dkk 3; ELISA; FOLR1; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; FOLATE RECEPTOR 1;

ADENOMYOSIS; ARTICLE; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CYST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; UTERUS MYOMA;

AREA UNDER THE CURVE; AUC; BIOMARKER; CA125; CARBOHYDRATE ANTIGEN 125; CI; CONFIDENCE INTERVAL; DIAGNOSTIC; DICKKOPF-RELATED PROTEIN 3; DKK-3; ELISA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FDA; FOLATE-RECEPTOR 1; FOLR1; FOOD AND DRUG ADMINISTRATION; NID2; NIDOGEN-2; ODDS RATIO; OR; OVARIAN CANCER; RECEIVER OPERATING CHARACTERISTIC; RISK OF MALIGNANCY ALGORITHM; ROC; ROMA;

ADULT; CA-125 ANTIGEN; CARCINOMA; CASE-CONTROL STUDIES; FEMALE; FOLATE RECEPTOR 1; GENE EXPRESSION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; OVARIAN NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84884355026     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.03.010     Document Type: Article

References (35)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Sevinc A., Adli M., Kalender M.E., Camci C. Benign causes of increased serum CA-125 concentration. Lancet Oncol 2007, 8:1054-1055.
3. Sevinc A., Buyukberber S., Sari R., Kiroglu Y., Turk H.M., Ates M. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. Gynecol Oncol 2000, 77:254-257.
4. Zuckerman E., Lanir A., Sabo E., Rosenvald-Zuckerman T., Matter I., Yeshurun D., et al. Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol 1999, 94:1613-1618.
5. Liede A., Karlan B.Y., Baldwin R.L., Platt L.D., Kuperstein G., Narod S.A. Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol 2002, 20:1570-1577.
6. Kulasingam V., Pavlou M.P., Diamandis E.P. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer 2010, 10:371-378.
7. Kuk C., Kulasingam V., Gunawardana C.G., Smith C.R., Batruch I., Diamandis E.P. Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol Cell Proteomics 2009, 8:661-669.
8. Kuk C., Gunawardana C.G., Soosaipillai A., Kobayashi H., Li L., Zheng Y., et al. Nidogen-2: a new serum biomarker for ovarian cancer. Clin Biochem 2010, 43:355-361.
9. Krupnik V.E., Sharp J.D., Jiang C., Robison K., Chickering T.W., Amaravadi L., et al. Functional and structural diversity of the human Dickkopf gene family. Gene 1999, 238:301-313.
10. Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 2006, 25:7469-7481.
11. Wu W., Glinka A., Delius H., Niehrs C. Mutual antagonism between dickkopf1 and dickkopf2 regulates Wnt/beta-catenin signalling. Curr Biol 2000, 10:1611-1614.
12. Mao B., Wu W., Li Y., Hoppe D., Stannek P., Glinka A., et al. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001, 411:321-325.
13. Hsieh S.Y., Hsieh P.S., Chiu C.T., Chen W.Y. Dickkopf-3/REIC functions as a suppressor gene of tumor growth. Oncogene 2004, 23:9183-9189.
14. Tsuji T., Miyazaki M., Sakaguchi M., Inoue Y., Namba M. A REIC gene shows down-regulation in human immortalized cells and human tumor-derived cell lines. Biochem Biophys Res Commun 2000, 268:20-24.
15. Tsuji T., Nozaki I., Miyazaki M., Sakaguchi M., Pu H., Hamazaki Y., et al. Antiproliferative activity of REIC/Dkk-3 and its significant down-regulation in non-small-cell lung carcinomas. Biochem Biophys Res Commun 2001, 289:257-263.
16. Nozaki I., Tsuji T., Iijima O., Ohmura Y., Andou A., Miyazaki M., et al. Reduced expression of REIC/Dkk-3 gene in non-small cell lung cancer. Int J Oncol 2001, 19:117-121.
17. Kurose K., Sakaguchi M., Nasu Y., Ebara S., Kaku H., Kariyama R., et al. Decreased expression of REIC/Dkk-3 in human renal clear cell carcinoma. J Urol 2004, 171:1314-1318.
18. Yue W., Sun Q., Dacic S., Landreneau R.J., Siegfried J.M., Yu J., et al. Downregulation of Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer. Carcinogenesis 2008, 29:84-92.
19. Zenzmaier C., Untergasser G., Hermann M., Dirnhofer S., Sampson N., Berger P. Dysregulation of Dkk-3 expression in benign and malignant prostatic tissue. Prostate 2008, 68:540-547.
20. Urakami S., Shiina H., Enokida H., Hirata H., Kawamoto K., Kawakami T., et al. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res 2006, 12:6989-6997.
21. Urakami S., Shiina H., Enokida H., Kawakami T., Kawamoto K., Hirata H., et al. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res 2006, 12:2109-2116.
22. Kobayashi K., Ouchida M., Tsuji T., Hanafusa H., Miyazaki M., Namba M., et al. Reduced expression of the REIC/Dkk-3 gene by promoter-hypermethylation in human tumor cells. Gene 2002, 282:151-158.
23. Lodygin D., Epanchintsev A., Menssen A., Diebold J., Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005, 65:4218-4227.
24. Jiang T., Huang L., Wang S., Zhang S. Clinical significance of serum Dkk-3 in patients with gynecological cancer. J Obstet Gynaecol Res 2010, 36:769-773.
25. Elnakat H., Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 2004, 56:1067-1084.
26. Bueno R., Appasani K., Mercer H., Lester S., Sugarbaker D. The alpha folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001, 121:225-233.
27. Hartmann L.C., Keeney G.L., Lingle W.L., Christianson T.J., Varghese B., Hillman D., et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer 2007, 121:938-942.
28. Toffoli G., Russo A., Gallo A., Cernigoi C., Miotti S., Sorio R., et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer 1998, 79:121-126.
29. Yang R., Kolb E.A., Qin J., Chou A., Sowers R., Hoang B., et al. The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate. Clin Cancer Res 2007, 13:2557-2567.
30. Kelemen L.E., Sellers T.A., Keeney G.L., Lingle W.L. Multivitamin and alcohol intake and folate receptor alpha expression in ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:2168-2172.
31. Konner J.A., Bell-McGuinn K.M., Sabbatini P., Hensley M.L., Tew W.P., Pandit-Taskar N., et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 2010, 16:5288-5295.
32. Turk M.J., Waters D.J., Low P.S. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett 2004, 213:165-172.
33. van Dam G.M., Themelis G., Crane L.M., Harlaar N.J., Pleijhuis R.G., Kelder W., et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med 2011, 17:1315-1319.
34. Basal E., Eghbali-Fatourechi G.Z., Kalli K.R., Hartmann L.C., Goodman K.M., Goode E.L., et al. Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One 2009, 4:e6292.
35. pROC: an open source package for R and S+ to analyze and compare ROC curves [Accessed September 13 2012]. http://www.biomedcentral.com/1471-2105/12/77/.